Regulatory support for the development of a stem cell therapy and device for the treatment of Parkinson’s Disease
![](https://boydconsultants.com/wp-content/uploads/2023/10/Website-news-cover-image-size-57.png)
Boyds provided regulatory support to an academic institution client with an exciting proposal for a first-in-human stem cell therapy trial involving a medical device for the treatment of Parkinson’s Disease.
Providing support for a phase 2 study in patients with metastatic breast cancer in the UK and EU
![](https://boydconsultants.com/wp-content/uploads/2023/08/Website-news-cover-image-size-45.png)
Boyds provided services to assist an EU Sponsor with the set up and ongoing site management of a study in patients with advanced metastatic breast cancer in the UK and Spain.
Strategic study start-up support in the UK and Europe
![study start-up support](https://boydconsultants.com/wp-content/uploads/2023/07/Website-news-cover-image-size-35.png)
Boyds was engaged to support a client in the US with study start-up services in the UK and France for a gene therapy study in patients with an ocular condition.
Combined gene therapy expertise supports US biotech
![Gene therapy expertise](https://boydconsultants.com/wp-content/uploads/2023/05/Website-news-cover-image-size-25.png)
The client was an early-stage start-up in the pre-clinical stage of developing a suite of gene therapy products for a cardiovascular indication.
Expansion of oncology clinical programme into other indications
![](https://boydconsultants.com/wp-content/uploads/2023/04/Website-news-cover-image-size-17.png)
The client came to Boyds with an exciting cell therapy programme that released its active molecule selectively in solid tumour cells.
Supporting new biotech companies spinning out of academia
![](https://boydconsultants.com/wp-content/uploads/2023/04/Website-news-cover-image-size-16.png)
Boyds played an important role in the formation of academia spin-out, Axovia, by providing technical and strategic support, alongside product development plans for the company’s drug programmes.
Product development support to benchmark novel medical food product
![](https://boydconsultants.com/wp-content/uploads/2023/03/Website-news-cover-image-size-13.png)
The client, an R&D driven FMCG company, approached Boyds to help them better understand how to successfully develop and position their novel medical food product in the market.
Boyds supports acquisition of UK-based oncology drug developer with scientific due diligence
![](https://boydconsultants.com/wp-content/uploads/2022/11/Website-news-cover-image-size-39.png)
Case study: Large company investments – Boyds supports the acquisition of UK-based oncology drug developer Background: The client was a large Asian-headquartered biopharmaceutical company, looking to grow through the purchase of multiple clinical and pre-clinical acquisitions. The target company with whom they wanted to engage with was a UK-based biotech company with assets in both […]
Assessment of novel vaccine technology triggers further investment
![](https://boydconsultants.com/wp-content/uploads/2022/11/Website-news-cover-image-size-38.png)
Case study: Assessment of novel vaccine technology triggers further investment Background: The client was a large multi-national fund, who has part ownership of a small biotech with a novel platform technology. The target company with whom they wanted to engage with was a European-based biotech company who were developing a novel technology platform to facilitate the […]
Boyds supports fledgling biotech company
![](https://boydconsultants.com/wp-content/uploads/2022/09/Website-news-cover-image-size-28.png)
Case study: Boyds supports fledgling biotech company to help build investable plan for venture capital firms and investors Background When trying to secure investment for your biotech from investors or a Venture Capital (VC) company it is essential to have a well-developed, integrated development plan describing how monies invested and entrusted to the development of […]